Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$53.89

1.41 (2.69%)

07:23
11/22/19
11/22
07:23
11/22/19
07:23

Biohaven Pharmaceutical initiated with an Outperform at Wedbush

Wedbush analyst Laura Chico initiated coverage of Biohaven Pharmaceutical with an Outperform rating and $75 price target. In a research note to investors, Chico says that she sees an attractive setup for shares with the potential arrival of oral, small molecule-targeted CGRP therapies that represents another step forward and with Biohaven's rimegepant under FDA review now. She models approval of rimegepant in FY20, with WW total revenue reaching $1.8B in FY27.

BHVN Biohaven Pharmaceutical
$53.89

1.41 (2.69%)

10/01/19
CANT
10/01/19
NO CHANGE
Target $87
CANT
Overweight
Cantor reiterates $87 target on Biohaven ahead of Phase 3 readout
After hosting a key opinion leader call to discuss prospects for rimegepant to potentially change the landscape for migraine prevention, Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Biohaven Pharmaceutical with an $87 price target. The analyst now has "enhanced conviction" on the Phase 3 readout in 2019 and believes rimegepant has the potential to disrupt the migraine treatment paradigm and open the door for oral anti-CGRP-based therapy to become the standard of care across the continuum in both acute and preventative settings.
10/04/19
ADAM
10/04/19
NO CHANGE
Target $80
ADAM
Buy
Biohaven Pharmaceutical entering catalyst rich Q4, says at Canaccord
Canaccord analyst Sumant Kulkarni noted Biohaven Pharmaceutical provided an update on the NDA for Rimegepant to be used in the treatment of migraines. The update suggested no major safety issues and said its priority review with an action date in Q1 remains on track. The analyst said a potential series of events in Q4 could create a nice setup for the shares. Kulkarni reiterated his Buy rating and $80 price target on Biohaven Pharmaceuticals shares.
10/28/19
CANT
10/28/19
NO CHANGE
Target $92
CANT
Overweight
Biohaven Pharmaceutical price target raised to $92 from $87 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Biohaven Pharmaceutical to $92 from $87 after hosting management in Europe for a week of investor meetings. The analyst has "enhanced conviction" about the company's potential value creation and reiterates an Overweight rating on the shares. Biohaven has a "better-than-even possibility" of being well prepared to launch rimegepant by establishing a commercially viable field force, possibly by the end of Q1 of 2020, and to having a "best-in-class" migraine drug, Duncan tells investors in a research note.
11/21/19
WEDB
11/21/19
INITIATION
Target $75
WEDB
Outperform
Biohaven Pharmaceutical initiated with an Outperform at Wedbush
Wedbush analyst Laura Chico initiated coverage of Biohaven Pharmaceutical with an Outperform rating and $75 price target.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/05/19
12/05
14:16
12/05/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$90.26

0.095 (0.11%)

, ADI

Analog Devices

$113.87

-0.03 (-0.03%)

14:13
12/05/19
12/05
14:13
12/05/19
14:13
Hot Stocks
Xilinx says will 'vigorously defend' self against Analog Devices patent suit »

Xilinx, Inc. (XLNX)…

XLNX

Xilinx

$90.26

0.095 (0.11%)

ADI

Analog Devices

$113.87

-0.03 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

  • 28

    Jan

PYPL

PayPal

$104.52

-0.46 (-0.44%)

14:07
12/05/19
12/05
14:07
12/05/19
14:07
Periodicals
Breaking Periodicals news story on PayPal »

Hedgeye names PayPal a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ALXN

Alexion

$107.06

-8.43 (-7.30%)

, REGN

Regeneron

$369.33

-0.67 (-0.18%)

14:03
12/05/19
12/05
14:03
12/05/19
14:03
Recommendations
Alexion, Regeneron analyst commentary  »

Piper Jaffray a buyer of…

ALXN

Alexion

$107.06

-8.43 (-7.30%)

REGN

Regeneron

$369.33

-0.67 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

CCEP

Coca-Cola European Partners

$50.07

-0.75 (-1.48%)

13:57
12/05/19
12/05
13:57
12/05/19
13:57
Periodicals
Einride to launch electric pod pilot with Coca-Cola European Partners, TC says »

Darrell Etherington of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,320.51

-0.95 (-0.07%)

13:37
12/05/19
12/05
13:37
12/05/19
13:37
Periodicals
Spain moving forward with 'Google tax' despite U.S. disappointment, El Pais says »

Spain is moving forward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEC

WEC Energy

$89.00

-0.07 (-0.08%)

13:32
12/05/19
12/05
13:32
12/05/19
13:32
Earnings
Breaking Earnings news story on WEC Energy »

WEC Energy sees FY20 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEC

WEC Energy

$88.97

-0.1 (-0.11%)

13:31
12/05/19
12/05
13:31
12/05/19
13:31
Hot Stocks
WEC Energy plans to raise quarterly dividend to 63.25c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$15.77

-0.05 (-0.32%)

13:31
12/05/19
12/05
13:31
12/05/19
13:31
Hot Stocks
Teck announces new collective agreement at Carmen de Andacollo operations »

Teck Resourcesannounced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

BIIB

Biogen

$298.44

9.09 (3.14%)

13:28
12/05/19
12/05
13:28
12/05/19
13:28
Recommendations
Biogen analyst commentary  »

Biogen doctor panel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

AAPL

Apple

$264.33

2.55 (0.97%)

13:28
12/05/19
12/05
13:28
12/05/19
13:28
Periodicals
Noted Apple analyst Kuo sees 2021 iPhone without lightning port, 9To5 Mac says »

Apple analyst Ming-Chi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
12/05/19
12/05
13:25
12/05/19
13:25
General news
Treasury Action: the markets have gone into a holding pattern »

Treasury Action: the…

13:25
12/05/19
12/05
13:25
12/05/19
13:25
Conference/Events
BTIG healthcare/biotech analysts to hold an analyst/industry conference call »

Analysts discuss the…

13:25
12/05/19
12/05
13:25
12/05/19
13:25
Conference/Events
Wolfe Research tech strategist to hold analyst/industry webcast »

Tech Strategist…

13:25
12/05/19
12/05
13:25
12/05/19
13:25
Conference/Events
House Financial Services Committee to hold a hearing »

The Subcommittee on…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/05/19
12/05
13:17
12/05/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.35

-2.54 (-0.73%)

13:17
12/05/19
12/05
13:17
12/05/19
13:17
Periodicals
Boeing to SEC: Doesn't see 737 MAX cancellations impacting revenue, Reuters says »

In a letter to the SEC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/05/19
12/05
13:16
12/05/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$311.24

-0.23 (-0.07%)

, SPX

S&P 500

$0.00

(0.00%)

13:12
12/05/19
12/05
13:12
12/05/19
13:12
General news
Mnuchin says U.S and China trade talks 'on track' after Thursday call »

U.S. Treasury Secretary…

SPY

SPDR S&P 500 ETF Trust

$311.24

-0.23 (-0.07%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRSC

Providence Service

$57.58

-0.39 (-0.67%)

13:06
12/05/19
12/05
13:06
12/05/19
13:06
Hot Stocks
LogistiCare to provide NEMT brokerage services to certain CCO members »

PacificSource Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$298.02

8.67 (3.00%)

13:06
12/05/19
12/05
13:06
12/05/19
13:06
Recommendations
Biogen analyst commentary  »

Stifel still sees lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

SAGE

Sage Therapeutics

$62.50

-86.72 (-58.12%)

12:55
12/05/19
12/05
12:55
12/05/19
12:55
Downgrade
Sage Therapeutics rating change  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$181.49

-2.79 (-1.51%)

12:55
12/05/19
12/05
12:55
12/05/19
12:55
Options
Constellation Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

12:55
12/05/19
12/05
12:55
12/05/19
12:55
General news
Atlanta Fed's Q4 GDP Nowcast now projects a 1.48% growth rate »

Atlanta Fed's Q4 GDP…

BIG

Big Lots

$18.89

-1.03 (-5.17%)

, GCO

Genesco

$37.08

0.52 (1.42%)

12:51
12/05/19
12/05
12:51
12/05/19
12:51
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BIG

Big Lots

$18.89

-1.03 (-5.17%)

GCO

Genesco

$37.08

0.52 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.